Znn3bq.jpeg
²é¿´: 1281  |  »Ø¸´: 5
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

polarmouse

Ìú³æ (³õÈëÎÄ̳)

[ÇóÖú] ÇóÁ½¶Î·­Ò룬·Ç³£½ô¼±£¬¸Ð¼¤ÌéÁã

In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A. Blood samples were taken over 72 h of each treatmentperiod. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80¨C1.25 ¡£
   Co-administration of A withB, C or D had no effect on A maximum plasma concentration (Cmax) or area under the plasma concentration-time curve (AUC). Similarly, A did not affect the Cmax or AUC for the co-administered drug, except for slight extensions of the 90% CI for the ratio of geometric means for B AUC (upper limit 1.29) andC Cmax (lower limit 0.75). All monotherapies and combination therapies were well tolerated.
    A can be co-administered with B¡¢C¡¢Dwithout dose adjustment of either drug

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Mally89

Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)

T_T

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
sltmac(½ð±Ò+41, ·­ÒëEPI+1): 2011-05-16 07:52:15
sltmac: ¼ÌÐøÅ¬Á¦~~ 2011-05-16 07:52:30
In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A¡£
ÔÚ½øÐгÖÐøÈý¸öÖÜÆÚ£¬Ëæ»ú¿ª·Å±ê¼ÇµÄÈý¸ö´¦Àí½»²æÖÎÁÆÑо¿µ±ÖУ¬10¸öÑù±¾ÖмÓÈë10mgµÄA£¬45mgµÄB»òÕß¶þÕߵĻìºÏÎÁíÍâ20¸öÑù±¾ÖмÓÈë20mgµÄA¡¢1000mgµÄC»òÕß¶þÕߵĻìºÏÎï¡£ÔÚÁíÒ»¸öËæ»ú¿ª·Å±ê¼Ç£¬Î¬³Ö5¸öÖÜÆÚµÄ5¸ö½»²æ²»Æ½ºâ´¦ÀíÑо¿µ±ÖУ¬Ê×ÏÈÏò12¸öÑù±¾ÖмÓÈë20mg A£¬4mg D»òÕß¶þÕß»ìºÏÎȻºóÔÙ¼ÓÈë100mgÎ÷ËûÁÐÍ¡»ò¼ÓÓÐ20mgAµÄÎ÷ËûÁÐÍ¡¡£
5Â¥2011-05-08 15:22:48
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 6 ¸ö»Ø´ð

Mally89

Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)

T_T

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

Blood samples were taken over 72 h of each treatment period. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80¨C1.25 ¡£
ÿ¸ö´¦ÀíÖÜÆÚ72Сʱ֮ºó½«ÑªÒºÑù±¾È¡³ö¡£¸ù¾Ý¼¸ºÎ·½·¨ºÍ»ìºÏÎï90%ÖÃÐÅÇø¼ä£¨ÔÚ0.8-1.25·¶Î§Äڵĵ¥Ò»ÖÎÁÆ£©µÄ±ÈÖµÀ´Åж¨½»²æ·´Ó¦ÖÐÊÇ·ñȱ·¦PK¡£
6Â¥2011-05-08 16:09:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁϹ¤³Ì281»¹Óе÷¼Á»ú»áÂð +29 xaw. 2026-04-11 30/1500 2026-04-13 00:20 by 1005715100
[¿¼ÑÐ] Ò»Ö¾Ô¸¹þ¹¤´ó 085600 277 12²Ä¿Æ»ùÇóµ÷¼Á 5+5 chenny174 2026-04-10 32/1600 2026-04-12 23:56 by BruceLiu320
[¿¼ÑÐ] 0831Ò»ÂÖµ÷¼Áʧ°ÜÇóÖú +10 СÐÜî£î£_s 2026-04-11 10/500 2026-04-12 22:43 by ³¤¹­°Á
[¿¼ÑÐ] Çóµ÷¼Á£¬985²ÄÁÏÓ뻯¹¤348·Ö +9 º­ÖñÁõ 2026-04-11 13/650 2026-04-12 22:40 by º­ÖñÁõ
[¿¼ÑÐ] ҩѧÇóµ÷¼Á +3 RussHu 2026-04-12 4/200 2026-04-12 17:49 by ³ÂƤƤ
[¿¼ÑÐ] 322Çóµ÷¼Á +6 123°²¿µ 2026-04-12 13/650 2026-04-12 15:51 by 123°²¿µ
[¿¼ÑÐ] Çóµ÷¼Á +16 ÕÅ·¬ÇѲ»³´µ° 2026-04-10 17/850 2026-04-12 13:58 by °¾Ò¹³É£¡
[¿¼ÑÐ] 305Çóµ÷¼Á +7 Â꿨°Í¿¨boom 2026-04-11 7/350 2026-04-12 07:35 by zhouxiaoyu
[¿¼ÑÐ] »¯Ñ§¹¤³Ìµ÷¼Á289 +44 yangæÃ 2026-04-07 50/2500 2026-04-12 02:36 by Çï¶¹²ËÑ¿
[¿¼ÑÐ] 305Çóµ÷¼Á +6 77Qi 2026-04-07 6/300 2026-04-12 02:30 by Çï¶¹²ËÑ¿
[¿¼ÑÐ] 26×ÔÈ»µØÀíѧ303·ÖÇóµ÷¼Á +6 Ò»Õ½³É˶°¡°¡°¡° 2026-04-06 11/550 2026-04-11 21:27 by Åáºêΰ
[¿¼ÑÐ] Çóµ÷¼Á +3 θ¾·ÂÎÀÛÁË 2026-04-11 5/250 2026-04-11 14:13 by luhong1990
[¿¼ÑÐ] 269µç×ÓÐÅÏ¢Çóµ÷¼Á£¬¿Éתרҵ +11 ¶À×Ãwl 2026-04-06 11/550 2026-04-11 11:12 by ÄæË®³Ë·ç
[¿¼ÑÐ] 0854µ÷¼Á +5 ÒôÏñµêÌý»¨¹ÄÏ· 2026-04-10 5/250 2026-04-11 10:49 by qingpingzhu
[¿¼ÑÐ] 275Çóµ÷¼Á +9 1624447980 2026-04-08 10/500 2026-04-11 10:20 by Delta2012
[¿¼ÑÐ] 083200 305·Ö Çó¶þÂÖµ÷¼Á ²»½ÓÊÜ¿çרҵ +9 Claireyyyy 2026-04-09 10/500 2026-04-10 21:21 by Claireyyyy
[¿¼ÑÐ] Çóµ÷¼Á288 +6 ioodiiij 2026-04-10 8/400 2026-04-10 21:07 by zhouxiaoyu
[¿¼ÑÐ] 283µç×ÓÐÅÏ¢Çóµ÷¼Á +4 ÈýʯWL 2026-04-08 4/200 2026-04-09 10:21 by wp06
[¿¼ÑÐ] ¿¼ÑÐÇóµ÷¼Á +4 ö©??? 2026-04-08 4/200 2026-04-08 21:44 by ÍÁľ˶ʿÕÐÉú
[¿¼ÑÐ] ±¾¿ÆÉúÎïÐÅϢѧ£¬×Ü·Ö362 Çó07 08µ÷¼Á +6 qСٻ1210 2026-04-06 6/300 2026-04-07 19:40 by macy2011
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û